Sense Proteomic Appoints the Sage Group as Business Development Consultants
News Jul 24, 2008
Sense Proteomic Ltd. announced the appointment of The Sage Group as its business development consultant to assist in generating additional biomarker discovery partners.
Building on its two external collaborations and its internal discovery programmes, Sense now hopes to partner with additional companies to fully exploit the power of its biomarker discovery platform.
Commenting on the appointment, Chris Lyddon, joint CEO, said, "We are pleased to be working with The Sage Group given their track record and their commercial expertise in the biomarker field. We believe discovery partners will shorten development timelines of both clinical diagnostics and biomarkers for clinical trials monitoring by applying our unique autoantibody biomarker technology."
Dr. Bill Mason, Executive Director of The Sage Healthcare Group added, "Sense's novel approach will allow diagnostic and pharmaceutical companies to develop more predictive markers in the important areas of cancer and autoimmune diseases. We are pleased to be working with them to help them achieve their goals."
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE